The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Successful biosimilar adoption in oncology: strategic approach to system standardization.
 
Suwicha Limvorasak
Research Funding - Pfizer
 
Crystal Leung Dobbs
No Relationships to Disclose
 
James Kim
No Relationships to Disclose
 
Edwin Melencio Posadas
No Relationships to Disclose
 
Hilary Teaford
No Relationships to Disclose
 
Marcio A. Diniz
No Relationships to Disclose
 
Andre Rogatko
No Relationships to Disclose
 
Bruce Vinson
No Relationships to Disclose
 
Leanne Sakamoto
No Relationships to Disclose
 
Vipul Patel
No Relationships to Disclose
 
Robert A. Figlin
Leadership - 4Dx; Apollomics
Stock and Other Ownership Interests - 4Dx
Consulting or Advisory Role - Bristol-Myers Squibb; CBT Pharmaceuticals; Johnson & Johnson
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Merck (Inst); Peloton Therapeutics (Inst)
 
Rita Shane
No Relationships to Disclose
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Merck KGaA; Mirati Therapeutics; Seagen; Takeda; Tesaro
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)